Get the Stockscreener App
17.94
2.87%
0.50
Pre-market:
18.50
0.56
+3.12%
Travere Therapeutics Inc stock is traded at $17.94, with a volume of 1.22M.
It is up +2.87% in the last 24 hours and down -16.17% over the past month.
See More
Previous Close:
$17.44
Open:
$17.17
24h Volume:
1.22M
Relative Volume:
0.81
Market Cap:
$1.55B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-3.9429
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
-13.71%
1M Performance:
-16.17%
6M Performance:
+29.34%
1Y Performance:
+154.83%
1-Day Range:
$17.07
$18.13
1-Week Range:
$17.07
$21.18
52-Week Range:
$5.12
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
17.94 | 1.55B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Trading (TVTX) With Integrated Risk Controls - news.stocktradersdaily.com
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts - Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - BioSpace
Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights - Yahoo Finance
When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com
Travere seeks FDA approval for potential FSGS treatment By Investing.com - Investing.com Australia
Travere rises on co's marketing application for kidney disease drug - TradingView
Travere seeks FDA approval for potential FSGS treatment - Investing.com India
Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS - Marketscreener.com
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - The Manila Times
Travere Therapeutics Submits sNDA for FILSPARI as Potential First FDA-Approved Treatment for FSGS - Nasdaq
Breakthrough: First-Ever FSGS Treatment Could Get FDA Green LightFILSPARI Shows Superior Results - StockTitan
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - Stock Titan
Travere Therapeutics at Leerink Conference: Filspari’s Promising Path - Investing.com
Focal Segmental Glomerulosclerosis Treatment Market Size - openPR
Is Eli Lilly Stock a Buy? - The Globe and Mail
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com
Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha
When the Price of (TVTX) Talks, People Listen - Stock Traders Daily
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 - Defense World
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat
Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World
Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan
Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat
Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Mirum Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Analyst Expectations For Travere Therapeutics's Future - Benzinga
Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada
Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN
Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey
Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
Travere therapeutics chief medical officer sells $60k in stock - MSN
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):